Wall Street analysts expect that BIOVERATIV INC (NASDAQ:BIVV) will announce $0.59 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for BIOVERATIV INC’s earnings. The company is scheduled to issue its next quarterly earnings report on Wednesday, August 2nd.

On average, analysts expect that BIOVERATIV INC will report full-year earnings of $2.33 per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will report earnings of $2.64 per share. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover BIOVERATIV INC.

A number of equities analysts recently commented on BIVV shares. Goldman Sachs Group, Inc. (The) cut BIOVERATIV INC from a “buy” rating to a “neutral” rating and set a $55.00 target price for the company. in a report on Monday, March 13th. Credit Suisse Group started coverage on BIOVERATIV INC in a report on Thursday, March 16th. They set an “underperform” rating and a $45.00 target price for the company. Piper Jaffray Companies upgraded BIOVERATIV INC from a “neutral” rating to an “overweight” rating and raised their target price for the company from $44.00 to $65.00 in a report on Monday, February 27th. Argus started coverage on BIOVERATIV INC in a report on Friday, March 31st. They set a “hold” rating and a $51.00 target price for the company. Finally, Zacks Investment Research upgraded BIOVERATIV INC from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a report on Wednesday, April 5th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $55.08.

In other BIOVERATIV INC news, Director Alexander J. Denner purchased 90,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 30th. The shares were purchased at an average cost of $55.93 per share, for a total transaction of $5,033,700.00. Following the completion of the purchase, the director now directly owns 5,001 shares in the company, valued at $279,705.93. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Louis J. Paglia purchased 2,000 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The stock was acquired at an average price of $57.76 per share, for a total transaction of $115,520.00. Following the completion of the purchase, the director now owns 3,056 shares of the company’s stock, valued at $176,514.56. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 94,000 shares of company stock worth $5,256,940.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate BIOVERATIV INC (BIVV) Will Announce Earnings of $0.59 Per Share” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/06/16/zacks-analysts-anticipate-bioverativ-inc-bivv-will-announce-earnings-of-0-59-per-share.html.

BIOVERATIV INC (BIVV) traded up 2.99% during mid-day trading on Tuesday, hitting $58.23. The company had a trading volume of 2,294,780 shares. The company has a 50-day moving average price of $56.10 and a 200 day moving average price of $53.19. BIOVERATIV INC has a 52-week low of $40.00 and a 52-week high of $59.50. The company has a market capitalization of $6.30 billion and a P/E ratio of 14.24.

About BIOVERATIV INC

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Get a free copy of the Zacks research report on BIOVERATIV INC (BIVV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related stocks with our FREE daily email newsletter.